Jianmin Pharmaceutical Group Co Ltd (600976) - Total Assets
Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) holds total assets worth CN¥4.69 Billion CNY (≈ $686.04 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jianmin Pharmaceutical Group Co Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Jianmin Pharmaceutical Group Co Ltd (600976) total market value for the company's overall valuation and market capitalisation.
Jianmin Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jianmin Pharmaceutical Group Co Ltd's total assets of CN¥4.69 Billion consist of 60.8% current assets and 39.3% non-current assets. Review 600976 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 2.5% |
| Accounts Receivable | CN¥1.18 Billion | 26.1% |
| Inventory | CN¥286.57 Million | 6.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥67.29 Million | 1.5% |
| Goodwill | CN¥214.03K | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Jianmin Pharmaceutical Group Co Ltd (600976) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jianmin Pharmaceutical Group Co Ltd's current assets represent 60.8% of total assets in 2025, a decrease from 64.7% in 2001.
- Cash Position: Cash and equivalents constituted 2.5% of total assets in 2025, down from 35.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 5.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 26.1% of total assets.
Jianmin Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Jianmin Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
Jianmin Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 1.65 | 1.48 |
| Quick Ratio | 1.36 | 1.46 | 1.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥987.05 Million | CN¥1.04 Billion | CN¥554.47 Million |
Jianmin Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jianmin Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.66 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 5.8% |
| Total Assets | CN¥4.53 Billion |
| Market Capitalization | $610.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jianmin Pharmaceutical Group Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jianmin Pharmaceutical Group Co Ltd's assets grew by 5.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jianmin Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total assets of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.53 Billion ≈ $662.43 Million |
+5.83% |
| 2024-12-31 | CN¥4.28 Billion ≈ $625.95 Million |
+2.63% |
| 2023-12-31 | CN¥4.17 Billion ≈ $609.90 Million |
+21.24% |
| 2022-12-31 | CN¥3.44 Billion ≈ $503.04 Million |
+21.66% |
| 2021-12-31 | CN¥2.83 Billion ≈ $413.47 Million |
+16.90% |
| 2020-12-31 | CN¥2.42 Billion ≈ $353.71 Million |
+25.34% |
| 2019-12-31 | CN¥1.93 Billion ≈ $282.21 Million |
+11.98% |
| 2018-12-31 | CN¥1.72 Billion ≈ $252.01 Million |
-10.50% |
| 2017-12-31 | CN¥1.92 Billion ≈ $281.56 Million |
+6.44% |
| 2016-12-31 | CN¥1.81 Billion ≈ $264.54 Million |
+12.84% |
| 2015-12-31 | CN¥1.60 Billion ≈ $234.43 Million |
+3.57% |
| 2014-12-31 | CN¥1.55 Billion ≈ $226.35 Million |
+7.02% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.51 Million |
+14.62% |
| 2012-12-31 | CN¥1.26 Billion ≈ $184.52 Million |
+7.94% |
| 2011-12-31 | CN¥1.17 Billion ≈ $170.95 Million |
+8.41% |
| 2010-12-31 | CN¥1.08 Billion ≈ $157.69 Million |
-16.86% |
| 2009-12-31 | CN¥1.30 Billion ≈ $189.66 Million |
+11.83% |
| 2008-12-31 | CN¥1.16 Billion ≈ $169.60 Million |
+30.86% |
| 2007-12-31 | CN¥885.70 Million ≈ $129.61 Million |
-15.79% |
| 2006-12-31 | CN¥1.05 Billion ≈ $153.91 Million |
-0.87% |
| 2005-12-31 | CN¥1.06 Billion ≈ $155.25 Million |
+14.76% |
| 2004-12-31 | CN¥924.49 Million ≈ $135.28 Million |
+73.57% |
| 2003-12-31 | CN¥532.62 Million ≈ $77.94 Million |
+17.36% |
| 2002-12-31 | CN¥453.85 Million ≈ $66.41 Million |
+13.91% |
| 2001-12-31 | CN¥398.42 Million ≈ $58.30 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.